Prot #BTCRC-HN17-111: Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-Positive Salivary Gland Carcinoma

Project: Research project

Project Details

StatusActive
Effective start/end date10/9/19 → 4/2/27

Funding

  • Hoosier Cancer Research Network, Inc. ((OE) Prot #BTCRC-HN17-111 // (OE) Prot #BTCRC-HN17-111)
  • Merck Sharp & Dohme Corporation ((OE) Prot #BTCRC-HN17-111 // (OE) Prot #BTCRC-HN17-111)